- $135.55m
- $118.16m
- $27.47m
U.S. STOCKS ON THE MOVE-Illumina, energy firms, Cue Biopharma
Cue Biopharma gains on FDA's 'fast track' tag for cancer drug candidate
U.S. RESEARCH ROUNDUP- Cooper Companies, Intuit, Nordson Corp
Brief: Cue Biopharma Doses First Patient In Phase 1 Study Of Cue-102 For Wilms' Tumor 1 (Wt1) - Expressing Cancers
Brief: Cue Biopharma Reports Second Quarter 2022 Financial Results
Brief: Cue Biopharma To Present At The 2022 American Society Of Clinical Oncology (Asco) Annual Meeting
Brief: Cue Biopharma Receives FDA Acceptance Of IND Application For CUE-102 In WT1
Brief: Cue Biopharma Reports First Quarter 2022 Financial Results
U.S. RESEARCH ROUNDUP- Air Products and Chemicals, Armstrong World Industries, Lennar
Cue Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Cue Biopharma Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Cue Biopharma Reports Two Objective Responses (1 Cpr And 1Upr) In First Interim Update From Dose Escalation Portion Of Ongoing Phase 1 Combination Study Of Cue-101 And Keytruda® In First Line Patients With Hpv+ Recurrent/Metastatic Head And Neck Cancer
Brief: Cue Biopharma To Host Business Update Call And Webcast For Ongoing Cue-101 Clinical Trials
Brief: Cue Biopharma And Lg Chem Life Sciences Announce Development Milestone In Immuno-Stat Biologics Collaboration For Cue-102
Brief: Cue Biopharma Announces Appointment Of Patricia Nasshorn As Chief Business Officer
Brief: Cue Biopharma Presents Updated Data From Lead Program CUE-101 Cancer Treatment At SITC Meeting
Brief: Cue Biopharma Enters Into Open Market Sale Agreement
U.S. STOCKS ON THE MOVE-Helbiz, Big Lots, AutoZone, Stoke Therapeutics
Cue Biopharma rises on new U.S. patents for lead cancer therapy